No Data
No Data
No Data
No Data
No Data
NexImmune (NEXI.US): The 2023 Q4 earnings report achieved revenue of $0, with a previous value of $0; earnings per share of -$4.99, with a previous value of -$16.25.
NexImmune (NEXI.US): The 2023 Q4 earnings report achieved revenue of $0, with a previous value of $0; earnings per share of -$4.99, with a previous value of -$16.25.
Zhitong FinanceApr 17 07:20
NexImmune Announces Leadership Shift in Financial Management
TipRanksApr 6 04:24
NexImmune Inc: Appointed Albert N. Marchio II As Interim CFO
NexImmune Inc: Appointed Albert N. Marchio II As Interim CFO
BenzingaApr 6 04:11
XXII, GRIN and XTIA Are Among Mid-day Movers
Seeking AlphaApr 6 02:55
NexImmune Has Received A Decision To Grant European Patent Number EP3970748 Titled "Nanoparticle Compositions And Methods For Immunotherapy"
NexImmune Has Received A Decision To Grant European Patent Number EP3970748 Titled "Nanoparticle Compositions And Methods For Immunotherapy"
BenzingaFeb 21 00:38
12 Health Care Stocks Moving In Monday's After-Market Session
GainersTrxade Health (NASDAQ:MEDS) stock rose 105.3% to $8.5 during Monday's after-market session. The company's market cap stands at $10.2 million. Iovance Biotherapeutics (NASDAQ:IOVA) shares moved
BenzingaFeb 20 05:30
No Data
No Data